An interleukin-10 gene polymorphism associated with the development of cervical lesions in women infected with Human Papillomavirus and using oral contraceptives

Infection, Genetics and Evolution

Volumn 19, Issue , 2013, Pages 32-37

  Chagas, Bárbara Simas ^a   Gurgel, Ana Pavla Almeida Diniz ^a   da Cruz, Heidi Lacerda Alves ^a   Amaral, Carolina Maria Medeiros ^a   Cardoso, Marcus Vinicius ^a   Neto, Jacinto da Costa Silva ^a   Silva, Luiz AntÔnio Ferreira da ^b   Albuquerque, Eugênia Maria Bezerra de ^c   Muniz, Maria Tereza Cartaxo ^d   Freitas, Antonio Carlos de ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^c University Hospital Oswaldo Cruz/Recife/Pernambuco   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Cervical cancer; Contraceptive; High resolution melting; Human Papillomavirus (HPV); Interleukin 10

Indexed keywords

INTERLEUKIN 10; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BRAZIL; CASE CONTROL STUDY; CERVICAL LESION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 58; INTERLEUKIN 10 GENE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE;

CERVICAL CANCER; CONTRACEPTIVE; HIGH RESOLUTION MELTING; HUMAN PAPILLOMAVIRUS (HPV); INTERLEUKIN-10;

ADULT; CONTRACEPTIVES, ORAL; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-10; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84880402174     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.06.016     Document Type: Article

References (43)

1. Barrett J.C., Frt B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
2. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005, 32S:S16-S24.
3. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., et al. The international biological study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 1995, 87:796-802.
4. Brinton L.A., Schairer C., Haenszel W., Stolley P., Lehman H.F., Levine R., et al. Cigarette smoking and invasive cervical cancer. JAMA 1986, 255:3265-3269.
5. Brisson J., Morin C., Roy M., Bouchard C., Leclerc J., Christen A., et al. Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions. Am J. Epidemiol. 1994, 140:700-710.
6. Chen Y.-H., Huang L.-H., Chen T.-M. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem. Biophys. Res. Commun. 1996, 224:621-659.
7. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C.G., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduces antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down regulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174:915-924.
8. Drysdale C.M., McGraw D.W., Stack C.B., et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. 2000, 97:10483-10488.
9. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum. Hered. 2008, 66:87-98.
10. El-Sherif A.M., Seth R., Tighe P.J., Jenkins D. Quantitative analysis of IL-10 and IFN-γ mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J. Pathol. 2001, 195:179-185.
11. Eskdale J., Kube D., Tesch H., Gallagher G. Mapping of the human IL 10 gene and further characterization of the 59 flanking sequence. Immunogenetics 1997, 46:120-128.
12. Eskdale J., Gallagher G., Verweij C.L., Keijsers V., Westendorp R.G.J., Huizinga T.W.J. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc. Natl. Acad. Sci. USA 1998, 95:9465-9470.
13. Fernandes A.P., Gonçalves M.A., Duarte G., Cunha F.Q., Simões R.T., Donadi E.A. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels. Virology 2005, 334:294-298.
14. Fernandes A.P., Golçaves M.A., Simões R.T., Mendes-Junior C.T., Duarte G., Donadi E.A. A pilot case-control association study of cytokine polymorphisms in Brazilian women presenting with HPV-related cervical lesion. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 140:241-244.
15. Freitas A.C., Gurgel A.P.A.D., Chagas B.S., Coimbra E.C., Amaral C.M.M. Susceptibility to cervical cancer: an overview. Gynecol. Oncol. 2012, 126:304-311.
16. Giannini S.L., Al-Saleh W., Piron H., Jacobs N., Doyen J., Boniver J., et al. Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression. Clin. Exp. Immunol. 1998, 113:183-189.
17. Giannini S.L., Hubert P., Doyen J., Boniver J., Delvenne P. Influence of the mucosal epithelium microenvironment on langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int. J. Cancer 2002, 97:654-659.
18. Gravitt P.E., Hildesheim A., Herrero R., Schiffman M., Sherman M.E., Bratti M.C., et al. Correlates of IL-10 and IL-12 concentrations in cervical secretions. J. Clin. Immunol. 2003, 23:175-183.
19. Hakama M., Lehtinen M., Knekt P., Aromaa A., Leinikki P., Miettinen A., et al. Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. Am. J. Epidemiol. 1993, 137:166-170.
20. Harmsel B.T., Smedts F., Kuijpers J., van Muyden R., Oosterhuis W., Quint W. Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia. Obstet. Gynecol. 1999, 93:46-50.
21. Hildesheim A., Reeves W.C., Brinton L.A., Lavery C., Brenes M., de La Guardia M.E., et al. Association of oral contraceptive use and human papillomavirus in invasive cervical cancers. Int. J. Cancer 1990, 45:860-864.
22. Hopman E.H., Rozendaal L., Voorhorst F.J., Walboomers J.M.M., Kenemans P., Helmerhorst T.J.M. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. Br. J. Obstet. Gynaecol. 2000, 107:600-604.
23. Howell W.M., Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J. Nutr. 2007, 137:194S-199S.
24. Hutchinson I.V., Pravica V., Hajeer A., Sinnott P.J. Identification of high and low responders to allografts. Rev. Immunogenet. 1999, 1:323-333.
25. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. J. Clin. 2011, 61:69-90.
26. Karlsen F., Kalantari M., Jenkins A., Pettersen E., Kristensen G., Holm R., et al. Use of multiple PCR primer sets for optimal detection of human papilomavírus. J. Clin. Microbiol. 1996, 34:2095-2100.
27. Manos M.M., Ting Y., Wright D.K., Lewis A.J., Broker T.R., et al. The use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989, 209-214.
28. Marks M.A., Gravitt P.E., Burk R.D., Studentsov Y., Farzadegan H., Klein S.L. Progesterone and 17β-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin. Vaccine Immunol. 2010, 17:609-617.
29. Matsumoto K., Oki A., Satoh T., Okada S., Minaguchi T., Onuki M., et al. Interleukin-10 - 1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn. J. Clin. Oncol. 2010, 40:1113-1116.
30. Mota F., Rayment N., Chong S., et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin. Exp. Immunol. 1999, 116:33-40.
31. Nardelli-Haefliger D., Wirthner D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus16 virus-like particles. J. Natl. Cancer Inst. 2003, 95:1128-1137.
32. Park J.S., Rhyu J.W., Kim C.J., Kim H.S., Lee S.Y., Kwon Y.I., et al. Neoplastic change of squamo-columnar junction in uterine cervix and vaginal epithelium by exogenous estrogen in HPV-18 URR E6/E7 transgenic mice. Gynecol. Oncol. 2003, 89:360-368.
33. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B. Cancer Incidence in Five Continents 2002, IARC, Lyon (France).
34. Roh J.W., Kim M.H., Seo S.S., Kim S.H., Kim J.W., Park N.H., et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002, 184:57-63.
35. Salazar E.L., González J.L., Olmos A., Calzada L. Influencia del uso de anticonceptivos orales como factores de riesgo para infección por virus del papiloma humano y neoplasia intraepitelial cervical. Ginecol. Obstet. Mex. 2005, 73:83-89.
36. Sharma A., Rajappa M., Saxena A., Sharma M. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int. J. Gynecol. Cancer 2007, 17:879-885.
37. Stanczuk G.A., Sibanda E.N., Perrey C., Chicara M., Pravica V., Hutchinson I.V., et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int. J. Cancer 2001, 94:792-794.
38. Szoke K., Szalmás A., Szládek G., Veress G., Gergely L., Tóth F.D., et al. IL-10 promoter nt- 1082A/G polymorphism and human papillomavirus infection in cytologic abnormalities of the uterine cervix. J. Interferon Cytokine Res. 2004, 24:245-251.
39. Thomas D.B., Ray R.M., Koetsawang A., et al. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18. Am. J. Epidemiol. 2001, 153:723-731.
40. Vossen R.H.A.M., Aten E., Roos A., den Dunnen J.T. High-resolution melting analysis (HRMA) - more than just sequence variant screening. Hum. Mutat. 2009, 30:1-7.
41. Wittwer C.T., Reed G.H., Gundry C.N., Vandersteen J.G., Pryor R.J. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin. Chem. 2003, 49:853-860.
42. Ylitalo N., Sorensen P., Josefsson A., et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int. J. Can. 1999, 81:357-365.
43. Zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta 1996, 1288:F55-F78.